Initial experience with 30 cases of transurethral blue laser vaporization of prostate for benign prostatic hyperplasia in a primary hospital
10.12483/j.issn.1009-8291.2026.06.007
- VernacularTitle:基层医院经尿道前列腺蓝激光汽化术治疗良性前列腺增生30例初步经验
- Author:
Fushen WANG
1
;
Mingqiang HOU
1
;
Binbin MAO
1
;
Huanhuan CAI
1
;
Qibo CAI
1
Author Information
1. Department of Urology, The People's Hospital of Xishui, Zunyi 564600, China
- Publication Type:Journal Article
- Keywords:
blue laser vaporization;
benign prostatic hyperplasia;
primary hospitals;
transurethral resection of prostate
- From:
Journal of Modern Urology
2026;31(6):542-546
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy and safety of transurethral blue laser vaporization of prostate (BVP) in the treatment of benign prostatic hyperplasia (BPH), and to explore the feasibility of its promotion in primary hospitals. Methods Clinical data of 30 BPH patients undergoing BVP in our hospital during Sep. and Dec. 2024 were retrospectively analyzed. The preoperative prostate volume, decrease in hemoglobin level 2 hours after operation, operation time, postoperative bladder irrigation time, catheter indwelling time, and intra-/postoperative complications were recorded. The changes of international prostate symptom score (IPSS), quality of life (QoL) score, and maximum urinary flow rate (Qmax) were compared before operation and 6 months after operation. Results The mean prostate volume was (46.9±15.7) mL. BVP was successfully completed in 28 patients. The 2 unsuccessful cases (6.7%) converted to transurethral resection of the prostate (TURP) due to intraoperative bleeding. For the 28 successful cases, the median postoperative 2-hour hemoglobin decrease was 4 (2, 11) g/L, mean operation time (59.8±13.2) min, median postoperative bladder irrigation time 21 (18, 23) h, median postoperative catheter indwelling time 5 (5, 5) d, and median postoperative hospital stay 6 (5, 6) d. After catheter removal, urinary retention with infection occurred in 1 case (3.6%), and hemorrhage in 1 case (3.6%). No severe complications occurred during the perioperative period. At 6 months postoperatively, the 28 patients showed significant improvement compared to preoperative values in IPSS[11 (10, 11) vs. 22 (21, 26), P＜0.001], QoL score[2 (2, 3) vs. 5 (5, 6), P＜0.001], and Qmax[ (17.2±5.6) mL/s vs. (7.8±1.4) mL/s, P＜0.001]. Conclusion BVP is a safe and effective treatment for BPH, offering advantages such as minimal blood loss, short operation time, and few complications. It effectively improves patients' lower urinary tract symptoms and quality of life, and is recommended for promotion in primary hospitals.
